• NanoMarkets

As the pharmaceutical industry matures, meeting Wall Street’s aggressive growth expectations becomes increasingly difficult. Many companies will continue to grow via merger and acquisition activity, and through internal development of highvalue compounds. Nonetheless, over the next decade, several blockbuster drugs will go off patent, resulting in an estimated loss of $30-$40 billion in annual product revenues as generic drugs enter the market.
Read more...